MarketCap
Facebook
X
Telegram
Happiness Biotech Group Limited Revenue | HAPP
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Happiness Biotech Group Limited
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.6 M | 71.5 K | - | - | 20.8 M | 71.5 M | 65.1 M | 63.9 M | 61.5 M | 53 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.5 M | 71.5 K | 43.8 M |
Quarterly Revenue Happiness Biotech Group Limited
| 2026-Q4 | 2026-Q2 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 12.4 M | 68.5 K | 71.5 K | - | - | - | 6.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.4 M | 68.5 K | 4.71 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Corcept Therapeutics Incorporated
CORT
|
761 M | $ 72.79 | 1.62 % | $ 7.56 B |  USA |
 |
Progenity, Inc.
PROG
|
74.3 M | - | -3.47 % | $ 164 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
30.7 M | - | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
9 M | $ 1.43 | 2.14 % | $ 128 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
13.5 K | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 56.03 | -0.16 % | $ 10.7 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
1.1 M | $ 1.15 | -0.86 % | $ 6.3 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
65.3 M | $ 10.99 | 9.03 % | $ 234 K | USA |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
678 M | $ 93.79 | 6.17 % | $ 6.96 B | USA |
 |
Lipocine
LPCN
|
1.98 M | $ 1.58 | 3.27 % | $ 8.61 M | USA |
 |
Seres Therapeutics
MCRB
|
789 K | $ 1.97 | -5.74 % | $ 17.5 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
958 M | $ 399.41 | -0.17 % | $ 8.96 B | USA |
 |
CEL-SCI Corporation
CVM
|
255 K | $ 1.44 | 6.67 % | $ 11.5 M | USA |
 |
Inventiva S.A.
IVA
|
9.2 M | $ 3.8 | 4.68 % | $ 227 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
81.4 M | $ 9.0 | 5.73 % | $ 724 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
5 K | $ 1.93 | 4.89 % | $ 2.53 M | USA |
 |
Eton Pharmaceuticals
ETON
|
80 M | $ 56.44 | 19.7 % | $ 1.52 B | USA |
 |
IDEAYA Biosciences
IDYA
|
219 M | $ 31.24 | 1.92 % | $ 2.76 B | USA |
 |
Foghorn Therapeutics
FHTX
|
30.9 M | $ 1.86 | -2.62 % | $ 117 M | USA |
 |
Ocugen
OCGN
|
4.41 M | $ 0.93 | 13.53 % | $ 291 M | USA |
 |
Minerva Neurosciences
NERV
|
41.2 M | $ 2.42 | 5.0 % | $ 20.5 M | USA |
 |
Kamada Ltd.
KMDA
|
180 M | $ 7.22 | 5.09 % | $ 416 M |  Israel |
 |
Neurocrine Biosciences
NBIX
|
2.86 B | $ 164.42 | 2.91 % | $ 16.4 B | USA |
 |
Nanobiotix S.A.
NBTX
|
32.6 M | $ 30.7 | 2.05 % | $ 1.47 T | France |
 |
Mereo BioPharma Group plc
MREO
|
36.5 M | $ 0.28 | 0.93 % | $ 223 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
186 M | $ 7.53 | 7.81 % | $ 1.09 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
49.8 M | $ 1.78 | 10.25 % | $ 646 M | USA |
 |
Nurix Therapeutics
NRIX
|
84 M | $ 15.3 | 3.1 % | $ 1.33 B | USA |
 |
Nkarta
NKTX
|
115 K | $ 1.75 | 11.15 % | $ 129 M | USA |
 |
MacroGenics
MGNX
|
150 M | $ 2.35 | 5.86 % | $ 148 M | USA |
 |
Protagonist Therapeutics
PTGX
|
46 M | $ 131.96 | -2.54 % | $ 8.39 B | USA |
|
Nuvation Bio
NUVB
|
62.9 M | $ 4.15 | -0.72 % | $ 1.42 B | USA |
 |
Novo Nordisk A/S
NVO
|
309 B | $ 40.36 | 0.21 % | $ 179 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
3.55 M | $ 0.91 | 0.95 % | $ 13.9 M | USA |
 |
NextCure
NXTC
|
22.4 M | $ 5.55 | 8.61 % | $ 15.8 M | USA |
 |
Kymera Therapeutics
KYMR
|
39.2 M | $ 132.5 | 3.42 % | $ 11.2 B | USA |
 |
Oragenics
OGEN
|
37.7 K | $ 0.35 | 0.29 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
7.25 M | $ 2.86 | 10.66 % | $ 372 M | USA |
 |
Relay Therapeutics
RLAY
|
15.4 M | $ 18.59 | 9.32 % | $ 3.19 B | USA |